The study reported that while ADSC infusion appeared safe, there were no significant differences in total length of hospital stay, ICU‐free days, and ventilator‐free days or in serum ARDS biomarkers (SP‐D, IL‐6, IL‐8) between treatment arms. This evidence concerns the gene IL6 and acute respiratory distress syndrome.